XML 98 R81.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Oct. 01, 2017 | Oct. 02, 2016 | Oct. 01, 2017 | Oct. 02, 2016
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1] | $ 13,168 | $ 13,045 | $ 38,843 | $ 39,196
Innovative Health and Essential Health [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 13,168 | 13,045 | 38,843 | 39,196
Innovative Health and Essential Health [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 1,285 | 1,240 | 3,810 | 3,730
Innovative Health and Essential Health [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 308 | 387 | 996 | 1,183
Innovative Health and Essential Health [Member] | Alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 741 | 419 | 2,112 | 1,155
Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 8,118 | 7,332 | 23,204 | 21,471
Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [5] | 5,050 | 5,712 | 15,639 | 17,725
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [6] | 2,681 | 2,708 | 7,995 | 8,373
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 491 | 422 | 1,341 | 1,294
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 238 | 244 | 711 | 751
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 226 | 238 | 684 | 714
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 82 | 110 | 253 | 300
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 83 | 91 | 241 | 273
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 76 | 70 | 215 | 207
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 78 | 72 | 215 | 228
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 61 | 56 | 202 | 203
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 50 | 83 | 193 | 248
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 58 | 55 | 164 | 163
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,237 | 1,268 | 3,776 | 3,992
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [7] | 1,273 | 1,461 | 4,270 | 4,481
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 109 | 102 | 352 | 330
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 114 | 102 | 345 | 304
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 79 | 80 | 221 | 240
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 60 | 69 | 192 | 203
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 51 | 64 | 182 | 199
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 860 | 1,044 | 2,977 | 3,206
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [8] | 794 | 1,023 | 2,398 | 3,224
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 134 | 191 | 428 | 623
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 102 | 89 | 285 | 286
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 212 | 194 | 564 | 550
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 97 | 140 | 305 | 459
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 69 | 174 | 230 | 546
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 68 | 94 | 220 | 334
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 58 | 73 | 189 | 213
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 55 | 68 | 176 | 214
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [9] | 141 | 83 | 367 | 228
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 112 | 49 | 284 | 130
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 28 | 34 | 82 | 97
CentreOne [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [10] | 161 | 156 | 514 | 540
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [11] | 0 | 281 | 97 | 879
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,455 | 2,243 | 7,245 | 6,557
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 1,150 | 1,049 | 3,382 | 3,107
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 644 | 449 | 1,813 | 1,225
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 240 | 198 | 727 | 631
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 206 | 297 | 711 | 897
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 79 | 63 | 198 | 175
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 62 | 60 | 187 | 191
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 75 | 128 | 228 | 330
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,649 | 1,641 | 4,385 | 4,576
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,522 | 1,536 | 4,069 | 4,302
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 43 | 33 | 119 | 102
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 85 | 72 | 197 | 172
Oncology [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,616 | 1,104 | 4,551 | 3,206
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 878 | 550 | 2,410 | 1,492
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 276 | 260 | 805 | 823
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 146 | 140 | 442 | 415
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 150 | 2 | 422 | 2
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 84 | 95 | 256 | 304
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 57 | 43 | 163 | 121
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 26 | 15 | 54 | 49
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,000 | 960 | 2,863 | 2,907
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 613 | 701 | 1,818 | 2,201
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 348 | 235 | 935 | 649
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 15 | 0 | 33 | 0
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 23 | 24 | 78 | 57
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 569 | 585 | 1,637 | 1,768
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 151 | 176 | 453 | 543
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 140 | 140 | 409 | 408
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 136 | 147 | 375 | 425
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 65 | 59 | 182 | 173
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 77 | 64 | 218 | 219
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | $ 829 | $ 798 | $ 2,522 | $ 2,457
[1] | Amounts may not add due to rounding.
[2] | Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3] | Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4] | The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
[5] | The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.
[6] | Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
[7] | Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
[8] | Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.
[9] | Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10] | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.
[11] | HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthandEssentialHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_LyricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ViagraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_InnovativeHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_DistinctBusinessAxis=pfe_EssentialHealthBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_LegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_LipitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PremarinFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_NorvascMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EpiPenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XalatanXalacomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EffexorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ZoloftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_RelpaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XanaxXanaxXRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_OtherLegacyEstablishedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_SterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_MedrolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_FragminMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_TygacilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PrecedexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherSterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_PeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_VfendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PristiqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ZyvoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_RevatioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherPeriLOEProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_BiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_InflectraRemsimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_CentreOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_EssentialHealthProductCategoryAxis=pfe_HospiraInfusionSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ChantixChampixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_BMP2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XalkoriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XtandiAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_InflammationandImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EucrisaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_RareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_BeneFIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_SomavertMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pfe_InnovativeProductsCategoryAxis=pfe_ConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |